Premium
Treatment of so‐called idiopathic follicular mucinosis with hydroxychloroquine
Author(s) -
Schneider S.W.,
Metze D.,
Bonsmann G.
Publication year - 2010
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2010.09759.x
Subject(s) - hydroxychloroquine , medicine , mycosis fungoides , dermatology , lymphoma , follicular phase , gastroenterology , disease , covid-19 , infectious disease (medical specialty)
Summary There exists no treatment of choice for follicular mucinosis (FM). Historically two distinct entities of FM have been proposed: FM of children and young adults not associated with other diseases (‘idiopathic’ FM), and FM in elderly patients associated with mycosis fungoides and Sézary syndrome (‘lymphoma‐associated’ FM). Nowadays it is suggested that ‘idiopathic’ FM might represent a localized form of cutaneous T‐cell lymphoma. Six patients with ‘idiopathic’ FM were treated with hydroxychloroquine (HCQ) at a dose of 200 mg three times daily for 10 days followed by a dose adjusted to the ideal body weight, usually 200 mg twice daily. All patients showed an improvement of ‘idiopathic’ FM already after 6 weeks and a complete remission with full hair regrowth after 2–5 months of HCQ therapy. In all patients no relapse occurred during follow up of between 3 and 23 years and no patient developed lymphoma. We conclude that HCQ is a highly effective therapy without significant side‐effects in the treatment of so‐called ‘idiopathic’ FM.